MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
$11,725K
Free Cash flow
-$60,589K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Net proceeds from stock issuance...
Sales and maturities of marketab...
Accounts payable and accrued exp...
Others
Negative Cash Flow Breakdown
Purchases of marketable securiti...
Net loss
Acquisition of property and equi...
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net loss
-73,503
-78,685
-81,317
-67,044
Depreciation and amortization
902
854
816
824
Amortization and premium of marketable securities, net
1,698
630
882
1,018
Loss on sale or disposal of assets
-1
-3
0
-6
Stock-based compensation expense
8,408
8,523
8,909
8,801
Accounts and other receivables
0
-1,785
1,925
0
Prepaid and other current assets
1,167
-6,283
-8,471
2,785
Other assets
0
2,076
3,994
64
Accounts payable and accrued expenses
10,137
-287
4,601
13,062
Other liabilities
-490
-1,358
1,381
-410
Net cash used in operating activities
-57,410
-65,588
-63,940
-48,628
Sales and maturities of marketable securities
150,510
133,366
111,500
116,915
Purchases of marketable securities
402,853
59,608
54,794
55,628
Acquisition of property and equipment
3,179
1,639
1,281
440
Net cash (used in) provided by investing activities
-255,522
72,119
55,425
60,847
Net proceeds from stock issuances
323,832
-
-
-
Proceeds from issuance of stock from employee benefit plans
825
327
1,349
774
Net cash provided by financing activities
324,657
327
1,349
774
Net increase (decrease) in cash and cash equivalents
11,725
6,858
-7,166
12,993
Cash and cash equivalents at beginning of period
35,729
28,871
36,037
28,356
Cash and cash equivalents at end of period
47,454
35,729
28,871
36,037
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Net proceeds from
stock issuances
$323,832K
Proceeds from issuance of
stock from employee...
$825K
(211.32%↑ Y/Y)
Net cash provided by
financing activities
$324,657K
(122412.08%↑ Y/Y)
Net increase
(decrease) in cash and cash...
$11,725K
(320.73%↑ Y/Y)
Canceled cashflow
$312,932K
Sales and maturities
of marketable...
$150,510K
(-59.09%↓ Y/Y)
Accounts payable and
accrued expenses
$10,137K
(252.85%↑ Y/Y)
Stock-based compensation
expense
$8,408K
(-54.57%↓ Y/Y)
Depreciation and
amortization
$902K
(-48.16%↓ Y/Y)
Loss on sale or
disposal of assets
-$1K
(83.33%↑ Y/Y)
Net cash (used in)
provided by investing...
-$255,522K
(-375.35%↓ Y/Y)
Net cash used in
operating activities
-$57,410K
(41.64%↑ Y/Y)
Canceled cashflow
$150,510K
Canceled cashflow
$19,448K
Purchases of marketable
securities
$402,853K
(46.98%↑ Y/Y)
Net loss
-$73,503K
(33.42%↑ Y/Y)
Acquisition of property and
equipment
$3,179K
(220.14%↑ Y/Y)
Amortization and premium of
marketable securities, net
$1,698K
(-57.07%↓ Y/Y)
Prepaid and other
current assets
$1,167K
(138.64%↑ Y/Y)
Other liabilities
-$490K
(71.58%↑ Y/Y)
Buy us a coffee
Celldex Therapeutics, Inc. (CLDX)
Celldex Therapeutics, Inc. (CLDX)